Your browser doesn't support javascript.
loading
A 96-week, double-blind, randomized controlled trial comparing bexagliflozin to glimepiride as an adjunct to metformin for the treatment of type 2 diabetes in adults.
Halvorsen, Yuan-Di; Lock, John Paul; Frias, Juan P; Tinahones, Francisco José; Dahl, Dominik; Conery, Annie L; Freeman, Mason W.
Affiliation
  • Halvorsen YD; Translational Medicine Group, Center for Computational and Integrative Biology, Massachusetts General Hospital, Boston, Massachusetts.
  • Lock JP; Theracos Sub, LLC, Marlborough, Massachusetts.
  • Frias JP; Velocity Clinical Research, Los Angeles, California.
  • Tinahones FJ; Hospital Virgen de la Victoria. Instituto de investigación Biomedica de Málaga IBIMA. Fisiopatología de la Obesidad y Nutrición (CIBERObn), Instituto de Salud Carlos III (ISCIII), Málaga University, Málaga, Spain.
  • Dahl D; Gemeinschaftspraxis fur lnnere Medizin und Diabetologie, Hamburg, Germany.
  • Conery AL; Translational Medicine Group, Center for Computational and Integrative Biology, Massachusetts General Hospital, Boston, Massachusetts.
  • Freeman MW; Translational Medicine Group, Center for Computational and Integrative Biology, Massachusetts General Hospital, Boston, Massachusetts.
Diabetes Obes Metab ; 25(1): 293-301, 2023 01.
Article in En | MEDLINE | ID: mdl-36178197
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Diabetes Mellitus, Type 2 / Metformin Type of study: Clinical_trials Limits: Humans Language: En Year: 2023 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Diabetes Mellitus, Type 2 / Metformin Type of study: Clinical_trials Limits: Humans Language: En Year: 2023 Type: Article